Show simple item record

dc.contributor.authorHealth Service Executive (HSE)
dc.contributor.authorMcGuire, E
dc.contributor.authorReilly, M
dc.date.accessioned2019-06-14T09:47:34Z
dc.date.available2019-06-14T09:47:34Z
dc.date.issued2019-05
dc.identifier.urihttp://hdl.handle.net/10147/624739
dc.descriptionCatatonia is a neuropsychiatric syndrome characterised by mutism, stupor, refusal to eat or drink, posturing and excitement or hypokinesis1. Clozapine is the only atypical antipsychotic licensed for treatment resistant schizophrenia. Unfortunately, it is associated with a number of side effects which can lead to poor compliance. There are a growing number of case reports highlighting the occurrence of catatonia following abrupt discontinuation of this medication.en_US
dc.language.isoenen_US
dc.publisherIrish Medical Journalen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectMENTAL HEALTHen_US
dc.subjectANTIPSYCHOTIC MEDICINESen_US
dc.subjectCATATONIAen_US
dc.subjectTREATMENT ADHERENCEen_US
dc.titleClozaril Withdrawal Induced Catatoniaen_US
dc.typeArticleen_US
dc.contributor.departmentSligo Leitrim Mental Health Serviceen_US
dc.identifier.journalIrish Medical Journalen_US
refterms.dateFOA2019-06-14T09:47:34Z


Files in this item

Thumbnail
Name:
art9.html
Size:
28.72Kb
Format:
HTML
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States